Skip to main content
Top
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

A functional microRNA library screen reveals miR-410 as a novel anti-apoptotic regulator of cholangiocarcinoma

Authors: Tiziana Palumbo, George A. Poultsides, Grigorios Kouraklis, Theodore Liakakos, Alexandra Drakaki, George Peros, Maria Hatziapostolou, Dimitrios Iliopoulos

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Cholangiocarcinoma is characterized by late diagnosis and a poor survival rate. MicroRNAs have been involved in the pathogenesis of different cancer types, including cholangiocarcinoma. Our aim was to identify novel microRNAs regulating cholangiocarcinoma cell growth in vitro and in vivo.

Methods

A functional microRNA library screen was performed in human cholangiocarcinoma cells to identify microRNAs that regulate cholangiocarcinoma cell growth. Real-time PCR analysis evaluated miR-9 and XIAP mRNA levels in cholangiocarcinoma cells and tumors.

Results

The screen identified 21 microRNAs that regulated >50 % cholangiocarcinoma cell growth. MiR-410 was identified as the top suppressor of growth, while its overexpression significantly inhibited the invasion and colony formation ability of cholangiocarcinoma cells. Bioinformatics analysis revealed that microRNA-410 exerts its effects through the direct regulation of the X-linked inhibitor of apoptosis protein (XIAP). Furthermore, overexpression of miR-410 significantly reduced cholangiocarcinoma tumor growth in a xenograft mouse model through induction of apoptosis. In addition, we identified an inverse relationship between miR-410 and XIAP mRNA levels in human cholangiocarcinomas.

Conclusions

Taken together, our study revealed a novel microRNA signaling pathway involved in cholangiocarcinoma and suggests that manipulation of the miR-410/XIAP pathway could have a therapeutic potential for cholangiocarcinoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cardinale V et al. Cholangiocarcinoma: increasing burden of classifications. Hepatobil Surg Nutr. 2013;2:272–80. Cardinale V et al. Cholangiocarcinoma: increasing burden of classifications. Hepatobil Surg Nutr. 2013;2:272–80.
2.
go back to reference Razumilava N, Gores GJ. Combination of gemcitabine and cisplatin for biliary tract cancer: a platform to build on. J Hepatol. 2011;54:577–8.CrossRefPubMed Razumilava N, Gores GJ. Combination of gemcitabine and cisplatin for biliary tract cancer: a platform to build on. J Hepatol. 2011;54:577–8.CrossRefPubMed
3.
go back to reference Komuta M et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes cancer. Hepatology. 2012;55:1876–88.CrossRefPubMed Komuta M et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes cancer. Hepatology. 2012;55:1876–88.CrossRefPubMed
5.
go back to reference Hatziapostolou M, Polytarchou C, Iliopoulos D. miRNAs link metabolic reprogramming to oncogenesis. Trends Endocrinol Metab. 2013;24:361–73.CrossRefPubMed Hatziapostolou M, Polytarchou C, Iliopoulos D. miRNAs link metabolic reprogramming to oncogenesis. Trends Endocrinol Metab. 2013;24:361–73.CrossRefPubMed
6.
go back to reference Haga H, Yan I, Takahashi Wood J, Patel T. Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma. Gene Expression. 2014;16:93–9.CrossRefPubMedPubMedCentral Haga H, Yan I, Takahashi Wood J, Patel T. Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma. Gene Expression. 2014;16:93–9.CrossRefPubMedPubMedCentral
7.
go back to reference Meng F et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006;130:2113–29.CrossRefPubMed Meng F et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006;130:2113–29.CrossRefPubMed
8.
go back to reference Selaru FM et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 2009;49:1595–601.CrossRefPubMedPubMedCentral Selaru FM et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 2009;49:1595–601.CrossRefPubMedPubMedCentral
10.
go back to reference Chen L et al. MiR-410 regulates MET to influence the proliferation and invasion of glioma. Int J Biochem Cell Biol. 2012;44:1711–7.CrossRefPubMed Chen L et al. MiR-410 regulates MET to influence the proliferation and invasion of glioma. Int J Biochem Cell Biol. 2012;44:1711–7.CrossRefPubMed
11.
go back to reference Gattolliat CH et al. Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. Br J Cancer. 2011;105:1352–61.CrossRefPubMedPubMedCentral Gattolliat CH et al. Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. Br J Cancer. 2011;105:1352–61.CrossRefPubMedPubMedCentral
12.
go back to reference Theodore SC et al. MicroRNA profiling of novel African American and Caucasian prostate cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltransferase 1. Oncotarget. 2014;5:3512–25.CrossRefPubMedPubMedCentral Theodore SC et al. MicroRNA profiling of novel African American and Caucasian prostate cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltransferase 1. Oncotarget. 2014;5:3512–25.CrossRefPubMedPubMedCentral
13.
14.
go back to reference Briggs CD et al. Prognostic molecular markers in cholangiocarcinoma: a systemic review. Eur J Cancer. 2009;45:33–47.CrossRefPubMed Briggs CD et al. Prognostic molecular markers in cholangiocarcinoma: a systemic review. Eur J Cancer. 2009;45:33–47.CrossRefPubMed
15.
go back to reference Kobayashi S, Werneburg NW, Bronk SF, Kauffman SH, Gores GJ. Interleukine-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005;128:2054–65.CrossRefPubMed Kobayashi S, Werneburg NW, Bronk SF, Kauffman SH, Gores GJ. Interleukine-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005;128:2054–65.CrossRefPubMed
16.
go back to reference Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-Term foe. Clin Cancer Res. 2009;15:425–30.CrossRefPubMed Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-Term foe. Clin Cancer Res. 2009;15:425–30.CrossRefPubMed
17.
go back to reference Seubwai W et al. Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF-Kb. Cancer Sci. 2010;101:1590–5.CrossRefPubMed Seubwai W et al. Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF-Kb. Cancer Sci. 2010;101:1590–5.CrossRefPubMed
18.
go back to reference Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 Homolog Bfl-1/A1 is a direct transcriptional target of NF-kB that blocks TNF-α induced apoptosis. Genes Dev. 1999;13:382–7.CrossRefPubMedPubMedCentral Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 Homolog Bfl-1/A1 is a direct transcriptional target of NF-kB that blocks TNF-α induced apoptosis. Genes Dev. 1999;13:382–7.CrossRefPubMedPubMedCentral
19.
go back to reference Stehlik C et al. Nuclear factor NF-kB-regulated X-chromosome–linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis. J Exp Med. 1998;188:211–6.CrossRefPubMedPubMedCentral Stehlik C et al. Nuclear factor NF-kB-regulated X-chromosome–linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis. J Exp Med. 1998;188:211–6.CrossRefPubMedPubMedCentral
21.
go back to reference Riedl SJ et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell. 2001;104:791–800.CrossRefPubMed Riedl SJ et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell. 2001;104:791–800.CrossRefPubMed
22.
23.
go back to reference Chien WW et al. Cyclin-dependent kinase1 expression is inhibited by p16INK4a at the post–transcriptional level through the microRNA pathway. Oncogene. 2011;30:1880–91.CrossRefPubMed Chien WW et al. Cyclin-dependent kinase1 expression is inhibited by p16INK4a at the post–transcriptional level through the microRNA pathway. Oncogene. 2011;30:1880–91.CrossRefPubMed
24.
go back to reference Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kB, inflammation and cancer. Nat Rev Cancer. 2010;10:561–74.CrossRefPubMed Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kB, inflammation and cancer. Nat Rev Cancer. 2010;10:561–74.CrossRefPubMed
26.
go back to reference Wu Z-H et al. ATM-and NEMO-dependent ELSK ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic Stress. Mol Cell. 2011;40:75–86.CrossRef Wu Z-H et al. ATM-and NEMO-dependent ELSK ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic Stress. Mol Cell. 2011;40:75–86.CrossRef
27.
go back to reference Bilim V, Kasahara T, Hara N, Takahashi K, Tomita Y. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer. 2003;103:29–37.CrossRefPubMed Bilim V, Kasahara T, Hara N, Takahashi K, Tomita Y. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer. 2003;103:29–37.CrossRefPubMed
28.
go back to reference La Casse EC et al. IAP-targeted therapies for cancer. Oncogene. 2008;27:6252–75.CrossRef La Casse EC et al. IAP-targeted therapies for cancer. Oncogene. 2008;27:6252–75.CrossRef
29.
go back to reference Hu Y et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clinical Cancer Res. 2003;9:2826–36. Hu Y et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clinical Cancer Res. 2003;9:2826–36.
30.
go back to reference Mansouri A, Zhang Q, Ridgway LD, Tian L, Claret F-X. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncology Res. 2003;13:399–404.CrossRef Mansouri A, Zhang Q, Ridgway LD, Tian L, Claret F-X. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncology Res. 2003;13:399–404.CrossRef
31.
go back to reference Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked Inhibitor of Apoptosis Protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 2000;60:5659–66.PubMed Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked Inhibitor of Apoptosis Protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 2000;60:5659–66.PubMed
32.
go back to reference Stenvang J, Silahtaroglu AN, Lindow M, Elmen J, Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol. 2008;18:89–102.CrossRefPubMed Stenvang J, Silahtaroglu AN, Lindow M, Elmen J, Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol. 2008;18:89–102.CrossRefPubMed
Metadata
Title
A functional microRNA library screen reveals miR-410 as a novel anti-apoptotic regulator of cholangiocarcinoma
Authors
Tiziana Palumbo
George A. Poultsides
Grigorios Kouraklis
Theodore Liakakos
Alexandra Drakaki
George Peros
Maria Hatziapostolou
Dimitrios Iliopoulos
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2384-0

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine